Open AccessSurvival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Author(s) -
Hao Xie,
Junjia Liu,
John R. Ogden,
Jun Yin,
Aminah Jatoi,
Joleen M. Hubbard,
Robert R. McWilliams,
Amit Mahipal,
Gloria M. Petersen,
Tanios BekaiiSaab,
Wen Wee
Publication year - 2020
Publication title -
american journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.896
H-Index - 78
eISSN - 1537-453X
pISSN - 0277-3732
DOI - 10.1097/coc.0000000000000708
Subject(s) - medicine , hazard ratio , chemotherapy , proportional hazards model , oncology , confidence interval , pancreatic cancer , performance status , cohort , clinical endpoint , cancer , surgery , clinical trial
Survival benefit of combination over single-agent chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC) was demonstrated in younger patients in clinical trials. The authors aimed to evaluate whether this survival benefit of combination chemotherapy is present in elderly patients with metastatic PDAC.